Lv5
1040 积分 2023-08-15 加入
Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer
2天前
已完结
HER-2 positive gastric cancer: Current targeted treatments
11天前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
6个月前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
6个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
6个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
6个月前
已完结
文献的附件Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
8个月前
已完结
Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial
8个月前
已完结
皖公网安备34019202002308
